It is also clear that SOCS3 expression is driven by aberrant JAK3/STAT3 activation in malignant T cells [62], whereas a nuclear expression and function of SOCS3 has never been reported in CTCL. This evidence concerns the gene SOCS3 and primary cutaneous T-cell non-Hodgkin lymphoma.